Relation Between Serum IGF-1 & BMI In Acne Vulgaris

December 3, 2023 updated by: Rania Sallam Mohamed Taha, Assiut University

Relation Between Serum Insulin Like Growth Factor 1 and Body Mass Index in Acne Vulgaris

cross-sectional study in which participants will be recruited at dermatology & Andrology out-patient clinics in Assuit university hospital, Egypt after patients examination by dermatologists & obtaining an informed consent

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 45 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Acne vulgaris patients aged from 15 to 45 years old

Description

Inclusion Criteria:

  1. Patients aged from 15 to 45 years old suffering from acne vulgaris.
  2. Both sexes.

Exclusion Criteria:

  1. Insulin resistance and diabetic patients
  2. Females with polycystic ovarian syndrome
  3. Treatment with drugs that can influence IGF-1level such as corticosteroid, insulin, hypoglycemic agents, and isotretinoin within one year before the date of study.
  4. Other causes of acne or acneform eruption as steroid-induced

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of serum level of insulin like growth factor 1 in acne vulgaris
Time Frame: 1 year
using the Chemiluminescent Microparticle Immunoassay
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2023

Primary Completion (Estimated)

May 30, 2024

Study Completion (Estimated)

May 30, 2024

Study Registration Dates

First Submitted

March 16, 2022

First Submitted That Met QC Criteria

March 26, 2022

First Posted (Actual)

March 29, 2022

Study Record Updates

Last Update Posted (Actual)

December 5, 2023

Last Update Submitted That Met QC Criteria

December 3, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IGF-1 in AV

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Evaluation of Serum Level of Insulin Like Growth Factor 1

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe